Janney Montgomery Scott covered BioDelivery Sciences International, Inc. (NASDAQ:BDSI), raising its target price to $4.00 today
- Updated: September 23, 2016
Boasting a price of $2.64, BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded 6.89% higher on the day. The last stock close price is down -3.18% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. BioDelivery Sciences International, Inc. has recorded a 50-day average of $2.55 and a two hundred day average of $2.71. Volume of trade was up over the average, with 1,206,545 shares of BDSI changing hands over the typical 774,850
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) had its stock price target increased to $4.00 by Janney Montgomery Scott in an issued report announced Friday September 23, 2016. The latest target price indicates a possible upside of 0.52% based on the company's last closing price.
On 5/12/2016, Piper Jaffray released a statement on BioDelivery Sciences International, Inc. (NASDAQ:BDSI) lowered the target price from $6.00 to $4.00. At the time, this indicated a possible upside of 0.92%.
See Chart Below
BioDelivery Sciences International, Inc. has with a one year low of $1.86 and a one year high of $7.04 and has a market capitalization of $0.
A total of 8 equity analysts have released a ratings update on the company. 3 firms rating the stock a strong buy, 4 brokerages rating the stock a buy, one equity analyst rating the company a hold, zero analysts rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $9.25.
Brief Synopsis On BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.